Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses a Change in Control Severance Agreement entered into with Todd Siefert on July 1, 2026, specifying compensatory arrangements including severance multiples (2.0x base salary and bonus), bonus payments, COBRA continuation, and accelerated equity vesting upon qualifying termination events. This is a classic executive compensation disclosure under Item 5.02(e), distinct from a departure or appointment, as it establishes the terms of a severance and change-of-control arrangement.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The disclosure centers on Board approval of new employment agreements for three named executives (Stuart A. Rose, Zafar A. Rizvi, and Douglas L. Bruggeman) that materially increase their compensatory arrangements, including annual maximum bonuses (Rose: $2.5M→$4M; Rizvi: $5M→$12M; Bruggeman: $2.5M→$4M), severance bonus caps, and termination benefits. This is a classic Item 5.02(e) compensatory arrangement disclosure, distinct from an appointment or departure.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-07-01
EX-99.1
The exhibit discloses a Board-approved grant of 2,475,000 stock options to the CEO at $4.32 per share with a ten-year term and four-year vesting schedule subject to performance milestones. This is a material compensatory arrangement for a named executive officer (CEO Francis Bellido) that would affect investor assessment of executive compensation and capital structure. While the exhibit also announces sponsorship of an industry summit, the substantive disclosure triggering SEC/regulatory reporting is the equity grant.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The disclosure centers on the Board's approval of a substantial equity grant of 9,099,328 RSUs to each of the two Co-CEOs (William Roberts and Daniel Roberts), subject to a six-year vesting and holding period. This is a compensatory arrangement for named executives under Item 5.02(e), distinct from an appointment or departure. The materiality is evident from the size of the grant, the multi-year vesting structure extending to 2033, and the Board's explicit statement that these grants are designed to retain and incentivize the Co-CEOs and align their interests with shareholders.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-01
The filing discloses a decision by the Compensation Committee to make an additional cash contribution of JPY 2.9 billion to a Board Benefit Trust (BBT) for the purpose of acquiring up to 350,000 shares of the Company for distribution to directors and executive officers under an existing stock compensation program. This is a material compensatory arrangement affecting named executives and directors, falling squarely within exec_compensation disclosure requirements.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-01
Item 5.02
SiTime adopted a deferred compensation plan effective July 1, 2026, allowing directors and named executive officers to defer base pay, bonus, and equity-based compensation, with the Company retaining the ability to make discretionary contributions.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-01
EX-99.2
Marex Group Limited adopted and shareholders approved the Global Omnibus Plan on 25 June 2026, a comprehensive equity incentive plan governing awards of options, restricted shares, conditional awards, and cash-based compensation to employees and directors, including performance conditions, vesting schedules, and clawback provisions.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-01
EX-99.4
Marex Group Limited adopted and shareholders approved the Long Term Incentive Plan on 25 June 2026, establishing the framework for equity-based compensation awards to eligible employees and directors, including performance conditions, vesting schedules, and malus and claw-back provisions.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-01
Item 5.02
The disclosure centers on a consulting agreement with F. Brad Denardo, the former President and CEO, establishing compensatory arrangements ($6,000 monthly consulting fee) for the Consulting Period (July 1, 2026 – June 30, 2027). While Denardo has already departed from executive roles, the principal disclosed action here is the formalization of his compensation structure as a consultant, not the departure itself. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses two compensatory arrangements for named executives: (1) a performance-based stock option award to CEO Arun Jeldi for 964,474 shares with market-capitalization-based vesting milestones, and (2) Change in Control Agreements with the CEO, CFO, and Chief Revenue Officer providing severance benefits upon qualifying terminations. These are classic executive compensation disclosures under Item 5.02(e), distinct from appointments or departures.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-01
EX-99.1
The announcement discloses compensatory arrangements agreed with Ron Edmonds in connection with his appointment as Interim Chief Financial Officer, including a USD$450,000 pro-rated base salary, short-term incentive up to 100% of fixed remuneration, and long-term incentive of USD$95,000 in director share rights subject to shareholder approval. This is a classic executive compensation disclosure under Item 5.02(e) equivalent, material to investors assessing executive costs and governance.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The Compensation Committee approved retention bonuses for named executives Eric Schlorff and Kevin Chung with vesting schedules and equity components under the 2022 Omnibus Incentive Plan. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from a departure or appointment. The retention structure and equity grants are material to investor assessment of executive incentives and capital allocation.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The disclosure centers on compensatory arrangements for the CEO and named executive officers, including restricted stock awards, incentive stock options, and base salary increases approved by the Board on June 26, 2026. The filing explicitly states the awards were granted "in order to align the economic interests" of executives with the Company and stockholders, and details the specific equity grants (174,081 restricted shares and 26,041 options for CEO Abinand Rangesh) and salary increases (5% for Rangesh to $220,500; 3% for other NEOs). This is a classic exec_compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses board approval of a new Executive Annual Incentive Plan on July 1, 2026, which establishes a compensatory arrangement for key executives. The disclosure details the plan's structure, performance measures, award thresholds, and administration by the Compensation Committee. This is a classic Item 5.02(e) compensation arrangement disclosure, distinct from executive departures or appointments.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-07-01
Item 5.02
The disclosure centers on an amendment to Tim Fisher's (COO) employment agreement that modifies his compensation and benefits through December 15, 2026, including extension of certain benefits and forfeiture of his 2026 annual equity grant and retention bonus. While the amendment also sets a terminal date for his employment, the substantive disclosure focuses on compensatory arrangements rather than a departure announcement, making exec_compensation the most salient classification.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-30
Item 5.02
The disclosure centers on a new employment agreement with Norman D. Lowery, the President and CEO, detailing his compensation ($698,987 annual base salary), severance arrangements, change-of-control protections (including a 2.99x multiplier), and other compensatory terms. While the agreement also addresses his continued employment, the substantive focus is on the compensatory arrangements and severance provisions, which is the hallmark of an exec_compensation event under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-30
Item 5.02
The disclosure centers on new employment agreements entered into on June 29, 2026 with three senior executives (Rodger A. McHargue, Stephen P. Panagouleas, and Mark A. Franklin) that establish compensatory arrangements including annual base salaries, bonus opportunities, severance terms, and change-of-control provisions. While the agreements also govern employment terms and termination conditions, the primary focus is the compensation structure and benefits, which is the hallmark of exec_compensation under Item 5.02(e).
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-30
Sony announced the granting of restricted stock units (RSUs) to directors, corporate executive officers, other officers, and employees across four series (Twentieth through Twenty-Third). The disclosure details vesting conditions, recipient categories, and share counts (totaling approximately 2.9 million shares across all series). This is a compensatory arrangement for named executives and employees under Sony's stock compensation plan, falling squarely within exec_compensation. The materiality is high given the scale of equity grants to senior leadership and the broad employee base affected.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-30
Item 8.01
NuCube's CEO Dr. Cristian Rabiti entered into an Employment Agreement detailing a compensation package including a $450,000 base salary, 100% target bonus, $21.4 million in restricted stock units, and severance and change-of-control provisions.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-30
EX-99.1
This announcement discloses a further grant of restricted stock units (RSUs) and share options under three equity compensation schemes (2021 RSU Scheme, 2022 RSU Scheme, and Post IPO Share Option Scheme) to directors, senior management, employees, and service providers. The disclosure includes specific grant details, vesting schedules, performance conditions, and clawback mechanisms. The grants to directors (including non-executive and independent non-executive directors) and senior management constitute material executive compensation arrangements requiring disclosure under Item 5.02(e) equivalent standards.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-30
Item 5.02
The Board of Directors approved new base salaries for four named executive officers effective July 1, 2026, including CEO W.M. 'Rusty' Rush at $1,855,802, along with adjustments for the CFO, COO, and SVP.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-30
The Board approved conversion of accrued but unpaid directors' fees totaling $542,500 into Series D-1 Preferred Stock (189,554 shares, convertible to 1,895,540 common shares) at $2.862 per share. This is a compensatory arrangement for directors involving equity issuance in satisfaction of outstanding cash compensation obligations, fitting the exec_compensation category under Item 5.02(e). The materiality is high given the substantial dollar amount and dilutive equity impact.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-30
Item 5.02
The board adopted and stockholders approved an amendment to the 2022 Omnibus Incentive Plan increasing the share reserve by 11,000,000 shares, from 10,033,333 to 21,033,333 shares, expanding equity incentive capacity for officers and directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-30
Item 5.02
The filing discloses an amendment to the Severance and Change in Control Agreement with CEO Richard Wilmer that removes the scheduled termination date and extends the agreement indefinitely until his separation. This is a material modification to compensatory and severance arrangements for a named executive officer, fitting the exec_compensation category. While the amendment does not involve a departure or appointment, it materially alters the CEO's severance protections and contingent compensation rights.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-30
Item 3.02
The Company issued 31,948 unregistered restricted shares to four independent directors as compensation for board service pursuant to the Independent Director Compensation Plan, with an aggregate value of $384,973.40 and vesting conditions tied to board service.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-29
Item 5.02
The disclosure centers on approval of a Discretionary Credit Award Agreement for Adam Heflin, a named executive officer, providing $1.5 million in discretionary credits vested over multiple years under the Deferred Compensation Plan. This is a compensatory arrangement—specifically an equity/deferred compensation award—not a departure or appointment. The material amount and multi-year vesting schedule make this material to investors.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-29
EX-99.1
This exhibit is a comprehensive Statement of Executive Compensation disclosing the compensation arrangements, policies, and awards for Mako Mining's named executive officers (CEO Akiba Leisman, CFO Ezequiel Sirotinsky, President Stephen Parsons, COO Jesse Munoz, and VP Exploration Frank Powell) for fiscal year 2025. It details base salaries, annual bonuses, equity-based awards (RSUs, DSUs, Options), performance metrics, and governance policies including a newly adopted clawback policy effective February 23, 2026. The Summary Compensation Table shows total compensation ranging from $676,717 to $2,623,649 across the NEOs, making this a material disclosure of executive compensation arrangements and awards.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-29
Item 5.02
The filing discloses compensatory arrangements for three named executives: salary increases (retroactive to April 1, 2026) for Serhii Kupriienko (CEO Global) from $250,000 to $375,000, Alexander Fink (CEO U.S. and President) from $250,000 to $375,000, and Brooks Ensign (CFO) from $250,000 to $300,000, along with target annual bonuses of 100%, 100%, and 50% of base salary respectively. These are material changes to executive compensation approved by the Compensation Committee and Board.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 90%
filed 2026-06-29
Item 5.02
The Board approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) modifying their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. Concurrently, the Board adopted a Change in Control Plan and a Severance Plan establishing compensatory arrangements for eligible employees with similar benefits.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-29
Item 5.02
The disclosure centers on compensatory arrangements for two interim executives: approval of Mr. Rothstein's salary of $30,000 per month and entry into an employment agreement with Mr. Weinmann specifying base salary of $300,000 per year, discretionary bonus structure, and severance terms. While the Item 5.02 heading also covers appointments, the substantive focus here is on the compensation terms approved and agreed to on June 24, 2026, making this primarily an exec_compensation event rather than exec_appointment (which was previously announced on June 16).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-26
Item 5.02
The filing discloses multiple compensatory arrangements approved by the HRCC effective June 24, 2026: (1) a TY26 annual cash incentive plan with target payouts ranging from 100–175% of base salary for six named executive officers; (2) a TY26–CY28 long-term equity program comprising PSUs and RSUs with target payouts of 200–450% of base salary; (3) Spin-Off bonuses (cash and RSUs) totaling up to $1 million for Mr. Smith; and (4) an Equity-Based Retirement Policy governing vesting treatment. These are core executive compensation matters within the scope of Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-26
Item 5.02
Ronald L. Sargent transitioned from Chief Executive Officer to Non-Executive Chairman with a new compensatory arrangement consisting of an annual retainer of $115,000 and incentive share grants valued at approximately $250,000.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-26
Item 5.02
The disclosure centers on compensatory arrangements for Jim Stephens, the Company's President of Cardiac Rhythm Management & Neuromodulation, including approval by the Compensation and Organization Committee of changes to his compensation in connection with a role transition to Executive Vice President, Special Projects, effective June 29, 2026, with a termination date of March 31, 2027, and exclusion from short-term and long-term incentive awards in 2027. While the filing also involves a role change, the principal disclosed action and the Committee's formal approval focus on the compensation modifications and severance-related terms (including the conditional "termination without Cause" treatment under the Change of Control Agreement), making this primarily a compensatory arrangement disclosure under Item 5.02(e).
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-06-26
EX-99.1
This exhibit is a written board resolution approving one-time performance bonuses for two named executives: Ms. Zhang Fan (Business Development Director) receives US$200,000 and Mr. Fu Xiaowei (CEO and Executive Director) receives US$300,000 for services rendered during 2025. The bonuses may be paid in cash or equivalent Class A ordinary shares. This is a direct disclosure of compensatory arrangements for named executives, fitting the exec_compensation category.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-26
Item 5.02
The Compensation Committee approved on June 22, 2026, a special leadership retention performance share award of 25,000 Performance Shares each for four named executives (Colin J. Souza, Patrick J. Kennedy, Steven M. Caravati, and James R. Bowes), subject to performance-based vesting conditions tied to adjusted EBITDA and return on assets targets for fiscal 2027–2030 and a retention condition.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-26
Item 5.02
Stockholders approved an amendment to the Myomo 2018 Stock Option and Incentive Plan increasing available shares by 1,833,000, expanding the pool of equity grants available to officers and directors.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-26
EX-99.1
This announcement discloses a grant of 1,890,627 restricted share units (RSUs) to certain employees of Bilibili Inc. pursuant to the Second Amended and Restated 2018 Share Incentive Plan on June 26, 2026. The grant represents approximately 0.45% of total shares outstanding and includes vesting schedules (June 2027–2030) and clawback provisions. This is a compensatory arrangement for employees and falls squarely within exec_compensation disclosure requirements, as it involves equity grants to incentivize and retain key personnel.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-26
Item 5.02
The Item 5.02 disclosure centers on two compensatory arrangements: (1) a new Executive Placement Agreement with SBR Limited for COO Jeroen Nieuwkoop providing $400,000 annual base salary, discretionary bonus up to 100% of base, and $1,000,000 annual equity awards plus $2,000,000 in initial RSU grants; and (2) a First Amendment to CEO David Schamis's employment agreement increasing his base salary to $600,000 and providing annual equity awards of $2,000,000–$3,000,000. These are material compensatory arrangements affecting named executives, not departures or appointments of new individuals.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-26
Item 5.02
The disclosure centers on a $4 million retention bonus agreement with Artem Yegorov, the Chief Technology Officer, contingent on his continued employment through the fourth anniversary of the effective date. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category. The materiality is clear given the size of the bonus and its strategic importance to retaining a key technology executive.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-26
Item 3.02
HeartSciences issued unregistered equity securities as compensatory awards to officers or directors, with the disclosure incorporating Item 5.02 by reference and relying on officer/director representations regarding the exemption.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The filing discloses amendments to compensatory arrangements for three named executives: Dr. Angelos Stergiou (President and CEO), John Burns (Senior Vice President and CFO), and Dr. Dragan Cicic (Senior Vice President and Chief Development Officer). The amendments modify severance and change-of-control benefits, including lump-sum payments, extended severance periods (9-18 months), bonus provisions, COBRA reimbursement, and equity acceleration upon termination. These are classic executive compensation arrangements subject to Item 5.02(e) disclosure and would materially affect investor assessment of executive retention costs and change-of-control obligations.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The Compensation Committee approved material changes to CFO John North's compensation package, including: (i) a base salary increase from $175,000 to $275,000 effective October 1, 2026; (ii) confirmation of a 100% annual target bonus opportunity; and (iii) modification of a market condition performance-vesting RSU arrangement with potential grants totaling up to $19.1 million ($1.6M + $7M + $10.5M) upon achievement of specified market capitalization, stock price, or EBITDA thresholds, plus additional change-of-control provisions. This is a classic executive compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The disclosure centers on amended and restated employment agreements for two named executives (CFO Conor Fennerty and Chief Investment Officer John Cattonar) that materially modify their compensation packages, including base salary increases ($600K→$650K and $500K→$550K), specified equity award targets (performance-based and time-based), and substantial backloaded restricted stock grants ($1.5M and $1.37M respectively with five-year vesting). This is a classic compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-25
Item 5.02
The combined company approved and implemented three equity incentive plans: the 2026 Incentive Award Plan (5,039,004 shares, 7% of post-Closing shares), the 2026 Employee Stock Purchase Plan (1,439,715 shares, 2% of post-Closing shares), and assumed the 2020 Equity Incentive Plan, all designed to attract and retain key personnel and approved by shareholders on June 16, 2026.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The Compensation Committee approved material changes to CEO Brent Lucas's compensation package, including an updated base salary of $420,000, a targeted cash bonus of $105,000, and equity grants of 1,000,000 stock options and 1,000,000 RSUs with performance-based vesting tied to FDA approval of the Acclaim cochlear implant. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-25
The filing discloses issuance of 25,000 shares of common stock to Bill Dyer, Chief Operating Officer, as a "transaction achievement bonus" pursuant to the Company's 2024 equity incentive plan, approved by the Board on June 16, 2026. This is a compensatory arrangement for a named executive officer under Item 5.02(e). The bonus is material as it represents equity compensation tied to a merger transaction (the XTEND Reality Expansion Ltd. agreement dated February 13, 2026).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-25
Item 5.02
The Compensation Committee approved cash retention bonus awards to named executive officers (Kim Kelderman, Jim Hippel, William Geist, Shane Bohnen, and Steve Crouse) totaling approximately $6.7 million, contingent on the contemplated Merger, including associated tax gross-up provisions.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-24
Item 5.02
The Company amended and restated executive employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III, effective June 24, 2026, increasing change-in-control severance benefits to 2x base salary plus target bonus with COBRA reimbursement up to 18 months, expanding flexibility for outside activities, and establishing a three-year initial term with automatic renewal.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-24
Item 5.02
The filing discloses compensatory arrangements for two named executives: Dr. Hartnett's new employment agreement (effective June 23, 2026) with a 3.0% base salary increase to $1,591,350 and modifications to performance-based compensation and equity award sizing; and Mr. Bergeron's amendment to his employment agreement with a 3.0% base salary increase to $713,482 and similar equity award modifications. These are classic Item 5.02(e) executive compensation disclosures affecting material terms of employment for senior officers.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-06-24
The 6-K discloses a Parachute Agreement (severance arrangement) entered into on June 19, 2026 between Genenta Science and Pierluigi Paracchi, the CEO and General Manager. The agreement specifies severance payments upon qualifying termination events (twelve months of gross remuneration plus target annual bonus up to 40% of annual gross remuneration), which constitutes a material compensatory arrangement for a named executive officer. While the filing also mentions an amendment to a non-compete covenant, the primary disclosure is the severance/parachute agreement, which falls squarely within executive compensation disclosures (Item 5.02(e) equivalent).
View raw filing on EDGAR →